- Created on the 12 March, 2017.
Interleukin-2 (IL-2) which was also originally known as T-cell growth factor, is produced by antigen- or lectin-activated T cells and is a powerfully immune-regulatory lymphokine. It is not only formed by the stimulation of mature T lymphocytes but also constitutively by a number of T-cell lymphoma cell lines. It has vital functions in the regulation of activation and proliferation of lymphocytes which have already been primed by antigens. Interleukin-2 also has a central role in the expansion of B-cells, T-cells and natural killer cells during certain phases of their response.
The human gene for interleukin 2 (IL-2) is located on chromosome 4. Human IL-2 is made up of 153 amino acids in the precursor form or 133 amino acids in the mature form and it is a 15.5KDa glycoprotein. Due to its central role in the immune response process, IL-2 has become a very important for many therapeutic and diagnostic implications. There is evidence to suggest that it may also display anti-tumoral effects which can be particularly useful in cancer therapy. By monitoring the levels of interleukin 2 in serum this can provide a better insight into several pathological situations such as rheumatoid arthritis, transplant rejection, cancer, multiple sclerosis, type I diabetes, systemic lupus erythematosus and infectious diseases. However, this issue with IL-2 toxicity is still a major concern and merit investigation.
Interleukin-2 ELISA kit is a method for determining in vitro quantitative amounts of interleukin-2 (IL-2) in human serum, cell culture supernatant, plasma (heparin, citrate, EDTA). This assay has a minimum detection limit of < 0.1 pg/ml.
The minimum detection sensitivity level of interleukin 2 (IL-2) using this human interleukin-2 ELISA kit was approximately 0.1 pg/ml. The dynamic assay range for this kit is 15.6 – 1,000 pg/ml.
- Central role for interleukin-2 in type 1 diabetes. Diabetes. (2012) 61 (1): 14-22. Review. Hulme M.A., et al.
- Inhibitors of interleukin-2 inducible T-cell kinase as potential therapeutic candidates for the treatment of various inflammatory disease conditions. Eur J Pharm Sci. (2012) 47 (3): 574-88. Review. Kaur M., et al.
- IL-2: the first effective immunotherapy for human cancer. J Immunol. (2014) 192 (12): 5451-8. Review. Rosenberg S.A.
- Interleukin 2 in cancer therapy. Curr Med Chem. (2010) 17 (29): 3297-302. Review. Antony G.K. and Dudek A.Z.
- The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). J Autoimmun. (2008) 31 (1): 7-12. Review. Lan R.Y., et al.
- The biology of interleukin-2. Annu Rev Immunol. (2008) 26: 453-79. Review. Malek T.R.
- Full Name: Interleukin-2 (IL-2) ELISA Kit
- Reactivity: Human
- Sample Type: Serum, Cell Culture Supernatant, Plasma (Citrate, EDTA, Heparin)
- Sensitivity: < 0.1 pg/ml